Shots: Recently at IDWeek 2024, ViiV Healthcare presented data from two real-world studies on Apretude, a long-acting injectable (LAI) for HIV pre-exposure prophylaxis. Dr. Harmony Garges, Chief Medical Officer at ViiV, shared insights from the presentations. The Opera cohort study found Apretude to be 99.7% effective in preventing HIV among participants. Additionally, the Trio Health…
